Back to Story
A pharmacist holds a vial of lenacapavir, the new HIV prevention injectable drug, at the Desmond Tutu Health Foundation's Masiphumelele Research Site, in Cape Town, South Africa, Tuesday, July 23, 2024. (AP Photo/Nardus Engelbrecht)

A pharmacist holds a vial of lenacapavir, the new HIV prevention injectable drug, at the Desmond Tutu Health Foundation's Masiphumelele Research Site, in Cape Town, South Africa, Tuesday, July 23, 2024. (AP Photo/Nardus Engelbrecht)

Lab technician, Xolile Mhlanga, works with vials of lenacapavir, the new HIV prevention injectable drug, at the Desmond Tutu Health Foundation's Masiphumelele Research Site, in Cape Town, South Africa, Tuesday, July 23, 2024. (AP Photo/Nardus Engelbrecht)

Lab technician, Xolile Mhlanga, works with vials of lenacapavir, the new HIV prevention injectable drug, at the Desmond Tutu Health Foundation's Masiphumelele Research Site, in Cape Town, South Africa, Tuesday, July 23, 2024. (AP Photo/Nardus Engelbrecht)

A pharmacist holds a vial of lenacapavir, the new HIV prevention injectable drug, at the Desmond Tutu Health Foundation's Masiphumelele Research Site, in Cape Town, South Africa, Tuesday, July 23, 2024, which was one of the sites for Gilead's lenacapavir drug trial. (AP Photo/Nardus Engelbrecht)

A pharmacist holds a vial of lenacapavir, the new HIV prevention injectable drug, at the Desmond Tutu Health Foundation's Masiphumelele Research Site, in Cape Town, South Africa, Tuesday, July 23, 2024, which was one of the sites for Gilead's lenacapavir drug trial. (AP Photo/Nardus Engelbrecht)

A pharmacist holds a vial of lenacapavir, at the Desmond Tutu Health Foundation's Masiphumelele Research Site, in Cape Town, South Africa, Tuesday, July 23, 2024. (AP Photo/Nardus Engelbrecht)

A pharmacist holds a vial of lenacapavir, at the Desmond Tutu Health Foundation's Masiphumelele Research Site, in Cape Town, South Africa, Tuesday, July 23, 2024. (AP Photo/Nardus Engelbrecht)

A pharmacist holds vials of lenacapavir, the new HIV prevention injectable drug, at the Desmond Tutu Health Foundation's Masiphumelele Research Site, in Cape Town, South Africa, Tuesday, July 23, 2024, which was one of the sites for Gilead's lenacapavir drug trial. (AP Photo/Nardus Engelbrecht)

A pharmacist holds vials of lenacapavir, the new HIV prevention injectable drug, at the Desmond Tutu Health Foundation's Masiphumelele Research Site, in Cape Town, South Africa, Tuesday, July 23, 2024, which was one of the sites for Gilead's lenacapavir drug trial. (AP Photo/Nardus Engelbrecht)

Clinical trials co-ordinator Thandeka Nkosi, stands in front of Lab technician, Xolile Mhlanga, who works with vials of lenacapavir, at the Desmond Tutu Health Foundation's Masiphumelele Research Site, in Cape Town, South Africa, Tuesday, July 23, 2024. The prospect of a twice-a-year shot is “quite revolutionary news” for our patients,” said Nkosi, who helped run the Gilead research at the Foundation in Masiphumelele. “It gives participants a choice and it just eliminates the whole stigma around taking pills” to prevent HIV. (AP Photo/Nardus Engelbrecht)

Clinical trials co-ordinator Thandeka Nkosi, stands in front of Lab technician, Xolile Mhlanga, who works with vials of lenacapavir, at the Desmond Tutu Health Foundation's Masiphumelele Research Site, in Cape Town, South Africa, Tuesday, July 23, 2024. The prospect of a twice-a-year shot is “quite revolutionary news” for our patients,” said Nkosi, who helped run the Gilead research at the Foundation in Masiphumelele. “It gives participants a choice and it just eliminates the whole stigma around taking pills” to prevent HIV. (AP Photo/Nardus Engelbrecht)

Lab technician, Xolile Mhlanga, works with vials of lenacapavir at the Desmond Tutu Health Foundation's Masiphumelele Research Site, in Cape Town, South Africa, Tuesday, July 23, 2024. Twice-yearly shots used to treat AIDS were 100% effective in preventing new infections in women, according to study results published Wednesday. (AP Photo/Nardus Engelbrecht)

Lab technician, Xolile Mhlanga, works with vials of lenacapavir at the Desmond Tutu Health Foundation's Masiphumelele Research Site, in Cape Town, South Africa, Tuesday, July 23, 2024. Twice-yearly shots used to treat AIDS were 100% effective in preventing new infections in women, according to study results published Wednesday. (AP Photo/Nardus Engelbrecht)